Zhihong Zhang - 17 Mar 2026 Form 3 Insider Report for Burning Rock Biotech Ltd (BNR)

Reporting relationship: Director
Issuer ticker: BNR
Reported as of: 17 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 17 Mar 2026, 10:00:11 UTC
Source filing: View source filing
Reporting owner signature: /s/ Yuheng Huang, Attorney-in-Fact for Zhihong Zhang

Key filing fact

Zhihong Zhang filed Form 3 for Burning Rock Biotech Ltd (BNR) on 17 Mar 2026.

Key facts

This page summarizes Zhihong Zhang's Form 3 filing for Burning Rock Biotech Ltd (BNR).
0 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 17 Mar 2026, 10:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002114639 Primary reporting owner

Zhang Zhihong

Relationship: Director
Address: 7720 VIA FRANCESCO UNIT 2, SAN DIEGO
Signature: /s/ Yuheng Huang, Attorney-in-Fact for Zhihong Zhang
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BNR holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,061,990
Date: 17 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BNR holding Derivative

OPTIONS (RIGHT TO BUY)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 78,504
Exercise price: $3.33
Footnotes: F1, F10

BNR holding Derivative

OPTIONS (RIGHT TO BUY)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 117,755
Exercise price: $3.33
Footnotes: F2, F10

BNR holding Derivative

OPTIONS (RIGHT TO BUY)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 78,504
Exercise price: $3.33
Footnotes: F3, F10

BNR holding Derivative

OPTIONS (RIGHT TO BUY)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 117,755
Exercise price: $3.33
Footnotes: F4, F10

BNR holding Derivative

OPTIONS (RIGHT TO BUY)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 78,504
Exercise price: $3.33
Footnotes: F5, F10

BNR holding Derivative

OPTIONS (RIGHT TO BUY)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 117,755
Exercise price: $3.33
Footnotes: F6, F10

BNR holding Derivative

OPTIONS (RIGHT TO BUY)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 51,469
Exercise price: $0.000200
Footnotes: F7, F10

BNR holding Derivative

OPTIONS (RIGHT TO BUY)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 41,000
Exercise price: $0.000200
Footnotes: F8, F10

BNR holding Derivative

OPTIONS (RIGHT TO BUY)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 56,000
Exercise price: $0.000200
Footnotes: F9, F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

On September 26, 2022, the Reporting Person was granted 78,504 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$2 billion by the fifth anniversary of the date of grant (the "valuation target"), and (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved.

Footnote F2

On September 26, 2022, the Reporting Person was granted 117,755 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$2 billion by the fifth anniversary of the date of grant (the "valuation target"), (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved, and (c) the Reporting Person has been employed by the Issuer for five years from the date of grant.

Footnote F3

On September 26, 2022, the Reporting Person was granted 78,504 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$4 billion by the seventh anniversary of the date of grant (the "valuation target"), and (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved.

Footnote F4

On September 26, 2022, the Reporting Person was granted 117,755 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$4 billion by the seventh anniversary of the date of grant (the "valuation target"), (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved, and (c) the Reporting Person has been employed by the Issuer for five years from the date of grant.

Footnote F5

On September 26, 2022, the Reporting Person was granted 78,504 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$10 billion by the seventh anniversary of the date of grants (the "valuation target"), and (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved.

Footnote F6

On September 26, 2022, the Reporting Person was granted 117,755 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$10 billion by the seventh anniversary of the date of grants (the "valuation target"), (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved, and (c) the Reporting Person has been employed by the Issuer for five years from the date of grant.

Footnote F7

On April 30, 2023, the Reporting Person was granted 102,938 share options, with 50%, 25% and 25% of the granted share options vesting on January 1, 2025, January 1, 2026 and January 1, 2027, respectively, subject to: (a) the Reporting Person's continued employment, and (b) the annual performance rating of the Reporting Person reaching at least 3.3 for each year from 2023 to 2026.

Footnote F8

On April 30, 2024, the Reporting Person was granted 41,000 share options, with 50%, 25% and 25% of the granted share options vesting on January 1, 2026, January 1, 2027 and January 1, 2028, respectively, subject to: (a) the Reporting Person's continued employment, and (b) the annual performance rating of the Reporting Person reaching at least 3.3 for the year of 2024.

Footnote F9

On April 30, 2025, the Reporting Person was granted 56,000 share options, with 50%, 25% and 25% on of the granted share options vesting January 1, 2027, January 1, 2028 and January 1, 2029, respectively, subject to: (a) the Reporting Person's continued employment, and (b) the annual performance rating of the Reporting Person reaching at least 3.3 for the year of 2025.

Footnote F10

Each share option represents the right to receive, upon exercise, one ordinary share.

SEC remarks

Exhibit 24 (Power of Attorney)

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .